Phase I study of safety and pharmacokinetics of the anti-MUC16 antibody-drug conjugate DMUC5754A in patients with platinum-resistant ovarian cancer or unresectable pancreatic cancer.
Saved in:
| Title: | Phase I study of safety and pharmacokinetics of the anti-MUC16 antibody-drug conjugate DMUC5754A in patients with platinum-resistant ovarian cancer or unresectable pancreatic cancer. |
|---|---|
| Authors: | Liu JF; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston joyce_liu@dfci.harvard.edu., Moore KN; Division of Gynecologic Oncology, Stephenson Oklahoma Cancer Center at the University of Oklahoma Health Sciences Center, Oklahoma City., Birrer MJ; Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston., Berlin S; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston.; Department of Oncology, New England Cancer Care Specialists, Kennebunk., Matulonis UA; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston., Infante JR; Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville., Wolpin B; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston., Poon KA; Early Development, Genentech, South San Francisco, USA., Firestein R; Early Development, Genentech, South San Francisco, USA., Xu J; Early Development, Genentech, South San Francisco, USA., Kahn R; Early Development, Genentech, South San Francisco, USA., Wang Y; Early Development, Genentech, South San Francisco, USA., Wood K; Early Development, Genentech, South San Francisco, USA., Darbonne WC; Early Development, Genentech, South San Francisco, USA., Lackner MR; Early Development, Genentech, South San Francisco, USA., Kelley SK; Early Development, Genentech, South San Francisco, USA., Lu X; Early Development, Genentech, South San Francisco, USA., Choi YJ; Early Development, Genentech, South San Francisco, USA., Maslyar D; Early Development, Genentech, South San Francisco, USA., Humke EW; Early Development, Genentech, South San Francisco, USA., Burris HA; Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville. |
| Source: | Annals of oncology : official journal of the European Society for Medical Oncology [Ann Oncol] 2016 Nov; Vol. 27 (11), pp. 2124-2130. |
| Publication Type: | Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Elsevier Country of Publication: England NLM ID: 9007735 Publication Model: Print Cited Medium: Internet ISSN: 1569-8041 (Electronic) Linking ISSN: 09237534 NLM ISO Abbreviation: Ann Oncol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
